



# Work Package n°3: WP: EVALUATION OF THE PROJECT

WP leader: Istituto Superiore di Sanità (ISS)





Timeline: Tasks, Deliverables & Milestones status

Stakeholders involvement

Risks encountered

Next steps for Year 2



### WP objectives



#### The main objectives of this WP are:

- to assess the achievement of the project objectives;
- to assess whether the outcomes meet the needs of the target groups.

#### The **specific objectives** of WP3 are:

- 1. Develop, share and disseminate an Evaluation Plan (EP);
- 2. Develop Evaluation Tools (ETs) for data collection;
- 3. Perform interim and final evaluation;
- 4. Develop quality assessment and report it;
- 5. Report on stakeholders evaluation;
- 6. Evaluate the impact of JA in Europe.





Task	Task Title	Duration
Task 3.1	Definition of the Evaluation Plan	M1 – M4
Task 3.2	Development of Evaluation Tools	M1 – M36
Task 3.3	Conduct interim and final evaluation	M5 – M36
Task 3.4	Quality assessment	M1 – M36
Task 3.5	Report on stakeholders evaluation	M18 – M36
Task 3.6	Evaluation of the JA impact in Europe	M18 – M36



### Task 3.1: Definition of the evaluation plan (EP)

Leader: ISS; Contributors: FFIS / Start date: M1 End date: M4

#### ✓ EP evaluates:

- the correct development of general and technical meetings;
- the respect of the calendar of JA milestones (support, early reaction, securing data);
- the respect of the defined timeline and deadlines for WPs activities and outputs.
- ✓ EP analyses needs, methods, and outcomes of each Work Package task, establishing the most relevant process, output and outcome indicators for each specific objective of the Joint Action.

EP has been reviewed and agreed by all the WPs leaders



### Task 3.2 Development of Evaluation Tools (M1 - M36)

Leader: ISS (subcontracting); Contributors: FFIS / Start date: M1 End date: M36

Based on the definition of the EP, the Evaluation Tools (Ets) have been developed to collect information through surveys and consultations among different participants and stakeholders.

Development of ETs Document and the following Annexes:

Annex 1 - EU-JAMRAI General Assembly Meeting Evaluation Questionnaire

Annex 2 - EU-JAMRAI Workshop/Conference Evaluation Questionnaire

Annex 3 - EU-JAMRAI Meeting/TC Brief Report

Annex 4 - EU-JAMRAI Quality assessment of the deliverable

Annex 5 - JA AMRAI HCAI Evaluation Checklist



The ETs and the Annexes have been shared among WPs leaders and revised according to their comments and suggestions



### Task 3.3: Conduct interim and final evaluation (M5 - M36)

Leader: FFIS; Contributors: UNIFG, ISS/ Start date: M5 End date: M36

- ✓ Based on results from evaluation activities, an interim and a final report including all collected information and indicators will be produced.
- ✓ Reports will be shared with internal and external stakeholders, including the Steering Committee and the Stakeholders forum. This will ensure that quality of JA output is always a top priority to the management bodies.



### Task 3.4: Quality Assessment

Leader: FFIS; Contributors: UNIFG, ISS / Start date: M1 End date: M36

- ✓ Deliverables and documentation are assessed for a set of quality aspects (e.g. comprehensibility, completeness, etc.) by the WP3 team, who will coordinate the evaluation involving relevant internal and external stakeholders.
- ✓ WP3 team has developed a document to support the Quality Assessment of JA documentation and deliverables.

The document has been shared among WPs leaders for comments and suggestions

uality

### Timeline: Tasks, Deliverables & Milestones status







## DELIVERABLES AND MILESTONES Y1 already done!

- √ D3.1 Evaluation plan
- √ D3.2 Validation of the evaluation tools
- √ D3.3 Progress monitoring and quality assessment of JA documentation and deliverables
- ✓ MS3.1 Agreement on ETs plan
- ✓ MS3.2 Availability of the web platform with tools to support the monitoring
- ✓ MS3.3 Periodic (every six months) check of correspondence between planned activities and timetable
- ✓ MS3.4 Identification of interested stakeholders
- ✓ MS3.5 Report on quality of the meetings within two months after their conclusion

### Next steps for year 2



No new DL

MS3.3 Periodic (every six months) check of correspondence between planned activities and timetable (M18, M24)

MS3.5 Report on quality of GA and Workshop/Conferences within two months after their conclusion (within 2 months).

MS3.6 Interim evaluation of JA (M19)



### **Stakeholders Involvement**



#### MS3.4 Identification of interested stakeholders

Organisation name	Contact name	Email address
ECDC	Dominique Monnet	DominiqueL.Monnet@ecdc.europa.eu
OECD	Michele Cecchini	Michele.CECCHINI@oecd.org
ЕРНА	Sascha Marschang	sascha@epha.org
WHO	Saskia Andrea NAHRGANG	nahrgangsa@who.int

### Risks (See Annex 2 of JAMRAI project)



#### •Risks Foreseen risks from the description of Work (Annex4)

Risk n°	Description of risk	Proposed risk mitigation measures	Comments/updates
WP3 (tasks 3.1 & 3.2)	Differences / non homogeneity among indicators adopted by different Work Packages for evaluation purposes	Dissemination and review of the EP (at the beginning of the JA) and the ETs (during the whole JA lifetime) will provide a common and shared set of measures for indicators.	
		Revision of the EP/ETs will be carried out if necessary to avoid differences among indicators used.	
		Consultation with SC and Stakeholders Forum on the harmonization of indicators proposed	
All WPs	Project status meetings at WP level to identify issues on the horizon	Project status meetings at WP level to identify issues on the horizon	

14 www.eu-jamrai.eu

### **WP3 Team**



- Istituto Superiore di Sanità (ISS) + University of Udine
- Fundacion para la Formacion and Investigation Sanitarias de la Region de Murcia (FFIS)
- University of Foggia (UNIFG)
- WP Leaders









Co-funded by the Health Programme of the European Union



\* This presentation arises from the Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI), which has received funding from the European Union, under the framework of the Health Program (2014-2020) under the Grant Agreement N° 761296. Sole responsibility lies with the author and the Consumers, Health, Agriculture and Food Executive Agency is not responsible for any use that may be made of the information contained herein.